For the quarter ending 2025-09-30, DMAA made $2,448,266 in revenue. $2,184,563 in net income. Net profit margin of 89.23%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| General and administrative costs | 263,703 | 131,919 | ||
| Loss from operations | -263,703 | -131,919 | ||
| Interest earned on cash and investments held in trust account | 2,448,266 | 2,420,498 | ||
| Total other income | 2,448,266 | 2,420,498 | ||
| Net income (loss) | 2,184,563 | 2,288,579 | ||
| Basic net income (loss) per ordinary share (in dollars per share) | 0.07 | - | ||
| Diluted net income per ordinary share (in dollars per share) | 0.07 | - | ||
| Weighted average ordinary shares outstanding basic (in shares) | 23,000,000 | - | ||
| Weighted average ordinary shares outstanding diluted (in shares) | 23,000,000 | - | ||
Drugs Made In America Acquisition Corp. (DMAA)
Drugs Made In America Acquisition Corp. (DMAA)